Everhart Financial Group’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$500K Sell
11,706
-4,457
-28% -$242K 0.03% 277
2026
Q1
$1.01M Sell
16,163
-924
-5% -$73.9K 0.09% 168
2025
Q4
$1.63M Buy
17,087
+226
+1% +$22.2K 0.15% 87
2025
Q3
$1.65M Buy
16,861
+277
+2% +$28.7K 0.17% 78
2025
Q2
$1.78M Buy
16,584
+754
+5% +$76.3K 0.21% 66
2025
Q1
$1.6M Buy
15,830
+722
+5% +$72.7K 0.22% 63
2024
Q4
$1.35M Buy
15,108
+932
+7% +$82K 0.28% 65
2024
Q3
$1.19M Buy
14,176
+1,412
+11% +$111K 0.26% 75
2024
Q2
$983K Buy
12,764
+1,100
+9% +$80.5K 0.26% 76
2024
Q1
$799K Buy
11,664
+4,093
+54% +$263K 0.23% 88
2023
Q4
$438K Buy
7,571
+1,043
+16% +$55.7K 0.16% 133
2023
Q3
$345K Buy
6,528
+1,219
+23% +$63.9K 0.15% 138
2023
Q2
$287K Buy
5,309
+548
+12% +$28.6K 0.12% 164
2023
Q1
$238K Buy
+4,761
New +$224K 0.11% 168
2022
Q4
Sell
-6,130
Closed -$238K 190
2022
Q3
$238K Buy
+6,130
New +$246K 0.13% 158

Other funds holding BSX

Everhart Financial Group's BSX Position: Q2 2026 in Review

Everhart Financial Group reduced its Boston Scientific (BSX) stake by 28% in Q2 2026, selling an estimated $242K and leaving 11,706 shares worth $500K. The position accounts for 0.03% of the portfolio, ranked #277.

Everhart Financial Group first reported a position in BSX in Q3 2022 and has held it in 15 quarters since. The position peaked at $1.78M in Q2 2025. 267 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Everhart Financial Group held 11,706 shares of Boston Scientific worth $500K as of Q2 2026.
  • Everhart Financial Group sold 4,457 Boston Scientific shares in Q2 2026, an estimated $242K.
  • Boston Scientific made up 0.03% of Everhart Financial Group's portfolio in Q2 2026, its #277 holding.
  • Everhart Financial Group first reported a position in Boston Scientific in Q3 2022 and has held it in 15 quarters since.
  • Everhart Financial Group's Boston Scientific position peaked at $1.78M in Q2 2025.
  • 267 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Everhart Financial Group's 13F filing for Q2 2026, filed 9 Jul 2026.